Is BPC-157 Legal in Missouri? How to Access It Legally

Is BPC-157 an approved drug?

No. FDA's July 2026 review found no approved product containing it in any country it searched, and no US Pharmacopeia or National Formulary monograph exists for it [1]. Websites selling BPC-157 capsules, injections and sprays labeled for research use only are not selling FDA-approved drugs [1].

Can a Missouri pharmacy compound it?

FDA's list of bulk substances nominated for compounding by state-licensed pharmacies, updated May 14, 2026, places BPC-157 in none of its three categories, including category 1, the group FDA generally will not act against compounders for when conditions are met [2]. BPC-157 was in category 2 (significant safety risks) from September 2023 until April 22, 2026. It then moved to a 'nominated but withdrawn' table after the nominators withdrew [5]. That move was not a finding of safety. FDA's concerns stay on the page: immunogenicity risk for certain routes of administration, peptide-related impurities and characterization problems, and only limited safety information [5].

What did the 2026 vote and HHS draft change?

On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to FDA's list, against FDA staff's recommendation [7][1]. The vote is advice only. BPC-157 is not on the list, and listing requires formal rulemaking [7][3].

On October 28, 2026 HHS filed a notice of a draft enforcement-discretion policy covering six peptides including BPC-157 [3]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the conditions are met [3]. The notice says the policy is not binding on HHS or the public and may be revisited, for example if a safety signal or product quality issue appears [3].

What are the draft policy's conditions for BPC-157?

The draft's conditions for BPC-157 are [4]:

• BPC-157 acetate only, as a single active ingredient.
• Subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous are not listed.
• Bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard.
• A patient-specific prescription.
• A label reading 'This is a compounded drug product. Not for resale.'
• Serious adverse events and quality problems reported to FDA MedWatch.
• Oral forms need documentation of adequate bioavailability.

The policy names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [3]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3].

How strong is the human evidence?

A systematic review searched to June 1, 2026 found 3 human studies covering 30 patients, of poor methodological quality, with certainty of evidence rated very low [8]. FDA's adverse-event search through December 4, 2025 found 3 reports, all injectable, and FDA said it cannot tell whether BPC-157 caused them. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' [1].

Is it allowed in sport?

WADA names BPC-157 in S0 (non-approved substances), prohibited at all times in and out of competition [6]. It stays named in the 2027 List [9].